Michelson Diagnostics

Michelson Diagnostics is a pioneer and world leader in applying Optical Coherence Tomography (OCT) to dermatology through its flagship VivoSight Dx system. The company, founded by a team of physicists and engineers, has established strong clinical validation with its technology cited in hundreds of peer-reviewed publications. It operates as a commercial-stage, revenue-generating private company, targeting both the clinical dermatology and skin research markets with a direct sales and support model. Michelson's strategy centers on deepening the utility of OCT imaging in skin health, from scar assessment to non-melanoma skin cancer management.

Proprietary multi-beam Optical Coherence Tomography (OCT) for high-resolution, in-vivo, cross-sectional imaging of skin up to 2mm depth. Platform includes hardware (VivoSight Dx scanner) and is developing AI-powered software for image analysis.

Michelson competes in the dermatology imaging market against other OCT manufacturers (e.g., Agfa, Thorlabs), high-frequency ultrasound systems, reflectance confocal microscopy (RCM) devices, and the established standard of dermoscopy. Its key differentiator is its specific focus on multi-beam OCT for dermatology and its substantial publication record. However, it must compete with larger companies for market share and clinician mindshare.